Baker Ellis Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Baker Ellis Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63K	Sell	16,000 -3,000	-16%	-$10.9K	0.01%	264
2026 Q1	$58.5K	Buy	+19,000	New	+$44.7K	0.01%	253

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Baker Ellis Asset Management's ELDN Position: Q2 2026 in Review

Baker Ellis Asset Management reduced its Eledon Pharmaceuticals (ELDN) stake by 16% in Q2 2026, selling an estimated $10.9K and leaving 16,000 shares worth $63K. The position accounts for 0.01% of the portfolio, ranked #264.

Baker Ellis Asset Management first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Baker Ellis Asset Management held 16,000 shares of Eledon Pharmaceuticals worth $63K as of Q2 2026.
Baker Ellis Asset Management sold 3,000 Eledon Pharmaceuticals shares in Q2 2026, an estimated $10.9K.
Eledon Pharmaceuticals made up 0.01% of Baker Ellis Asset Management's portfolio in Q2 2026, its #264 holding.
Baker Ellis Asset Management first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Baker Ellis Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.